Auckland, New Zealand, September 14, 2022 /PRNewswire/ — New Zealand Soft Tissue Regeneration Company Aroa Biosurgery (AROA) is delighted to announce the appointment of award-winning medical researcher and inventor, Dr. Catherine Mohr as non-executive director of the board of directors.

AROA’s products are developed from a proprietary technology platform AROA ECM™, a novel extracellular matrix biomaterial derived from ovine (sheep) fore-stomach. More than 5 million AROA devices have been applied in the treatment of patients to date.

Born in New ZealandDr. Mohr, who lived in United States for many years, earned his BSc and MSc in Mechanical Engineering from Massachusetts Institute of Technology (MIT) and his medical doctor from Stanford University Medicine School.

Dr. Mohr’s experience extends multiple areas including surgery, medical technology, engineering, product development and design, healthcare, alternative energy, automotive, aerospace, global entrepreneurship, intellectual property litigation , US Food & Drug Administration compliance and education.

Dr. Mohr has been involved in several successful start-up companies in medical technology and beyond, including co-founding VeriSure, where she invented the LapCap™, the first of a new class of products enabling laparoscopic surgery .

On joining the AROA Board of Directors, Dr Mohr said: “I have watched the history of AROA unfold with interest and look forward to being involved in the future of this organization. innovation at the forefront of regenerative healing”.

Dr. Mohr is currently Chairman of the Intuitive Foundation, the Silicon Valley-based corporate foundation of Intuitive Surgical, a pioneer in robotic-assisted surgery and maker of the da Vinci Surgical Robot System.

Prior to leading the Foundation, Dr. Mohr was a key member of the Intuitive Surgical leadership team for over 12 years. Beginning her tenure in 2006, Dr. Mohr held several leadership positions, including those of Vice President of Strategy and Director of Medical Research, making a significant contribution to the growth of the organization.

CEO of AROA Dr. Brian Ward says, “Dr. Mohr’s diverse skillset and extensive research and development experience will be tremendous assets to AROA. Everybody“.

Dr. Ward’s sentiments are echoed by the chairman of the board Jim McLean which says, “We welcome the extensive international experience and valuable knowledge that Dr. Mohr brings to the AROA Board of Directors.”

Dr. Mohr’s appointment to the Board of Directors is expected to take effect on November 1, 2022, after meeting the Australian General Counsel ID number requirements. Dr. Mohr will stand for election as shareholders at the upcoming AROA Annual Meeting at or around August 2023.

SOURCE Aroa Biosurgery